Oculis Holding AG
SWB:CR5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Oculis Holding AG
SWB:CR5
|
CH |
|
Q
|
Q2 Holdings Inc
F:0Q2
|
US |
|
Mitsui Fudosan Co Ltd
TSE:8801
|
JP |
|
FibroGen Inc
LSE:0IL8
|
US |
|
Aeon Co Ltd
OTC:AONNF
|
JP |
|
ProQR Therapeutics NV
F:0PQ
|
NL |
|
Elixirr International PLC
LSE:ELIX
|
UK |
|
R
|
Reach PLC
F:MRR
|
UK |
|
10X Genomics Inc
LSE:0A88
|
US |
Wall St Price Targets
CR5 Price Targets Summary
Oculis Holding AG
According to Wall Street analysts, the average 1-year price target for CR5 is 32.87 EUR with a low forecast of 22.53 EUR and a high forecast of 40.55 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CR5's stock price target?
Price Target
32.87
EUR
According to Wall Street analysts, the average 1-year price target for CR5 is 32.87 EUR with a low forecast of 22.53 EUR and a high forecast of 40.55 EUR.